| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 94.83 mm | 94.83 mm | 94.83 mm | 94.83 mm | 94.83 mm | 94.83 mm |
| Cash burn (monthly) | 11.49 mm | 1.10 mm | 9.74 mm | 8.59 mm | 7.04 mm | 7.13 mm |
| Cash used (since last report) | 50.35 mm | 4.82 mm | 42.68 mm | 37.65 mm | 30.85 mm | 31.24 mm |
| Cash remaining | 44.48 mm | 90.01 mm | 52.15 mm | 57.18 mm | 63.97 mm | 63.59 mm |
| Runway (months of cash) | 3.9 | 81.9 | 5.4 | 6.7 | 9.1 | 8.9 |
| 13F holders | Current |
|---|---|
| Total holders | 82 |
| Opened positions | 22 |
| Closed positions | 14 |
| Increased positions | 19 |
| Reduced positions | 20 |
| 13F shares | Current |
|---|---|
| Total value | 116.52 bn |
| Total shares | 62.39 mm |
| Total puts | 6.00 k |
| Total calls | 23.20 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| TCG Crossover GP II | 20.76 mm | $390.36 mm |
| Venrock Healthcare Capital Partners III | 15.56 mm | $0.00 |
| Frazier Life Sciences Public Fund | 5.00 mm | $9.86 mm |
| BML Capital Management | 2.27 mm | $15.92 bn |
| BML Investment Partners | 2.10 mm | $18.45 mm |
| TCG Crossover Management | 2.01 mm | $14.10 bn |
| REGN Regeneron Pharmaceuticals | 1.81 mm | $3.18 mm |
| BEN Franklin Resources | 1.76 mm | $13.61 bn |
| BlackRock | 1.49 mm | $10.46 bn |
| VR Adviser | 1.47 mm | $10.30 bn |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Aug 24 | Rabia Gurses Ozden | Stock Option Common Stock | Grant | Acquire A | No | No | 7.15 | 44,010 | 314.67 k | 44,010 |
| 2 Aug 24 | Linda M Rubinstein | Stock Option Common Stock | Grant | Acquire A | No | No | 7.15 | 62,083 | 443.89 k | 62,083 |
| 2 Aug 24 | Setareh Seyedkazemi | Stock Option Common Stock | Grant | Acquire A | No | No | 7.15 | 43,458 | 310.72 k | 43,458 |
| 2 Aug 24 | Peter Soparkar | Stock Option Common Stock | Grant | Acquire A | No | No | 7.15 | 64,394 | 460.42 k | 64,394 |
| 2 Aug 24 | Fischer Laurent | Stock Option Common Stock | Grant | Acquire A | No | No | 7.15 | 200,000 | 1.43 mm | 200,000 |
